Sotrovimab Use in Young Pediatric Patients at High Risk of Progression to Severe COVID-19 Disease

This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).

Automated summary

This retrospective analysis examines the use of sotrovimab in 32 at-risk children with COVID-19, providing dosing recommendations and demonstrating its feasibility in the pediatric population under 12 years old and under 40 kg.